Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ATRA
- Price
- 6.17
- Stock movement up
- +0.33 (5.65%)
- Company name
- Atara Biotherapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 35.54M
- Ent value
- 222.33M
- Price/Sales
- 0.35
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -54.36%
- 1 year return
- -63.79%
- 3 year return
- -68.91%
- 5 year return
- -51.17%
- 10 year return
- -40.95%
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ATRA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.35 |
| Price to Book | - |
| EV to Sales | 2.21 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 5.76M |
| EPS (TTM) | -128.98 |
| FCF per share (TTM) | -12.70 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 100.44M |
| Gross profit (TTM) | 83.06M |
| Operating income (TTM) | -119.76M |
| Net income (TTM) | -962.98M |
| EPS (TTM) | -128.98 |
| EPS (1y forward) | -9.18 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 82.70% |
| Operating margin (TTM) | -119.24% |
| Profit margin (TTM) | -958.77% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 46.45M |
| Net receivables | 1.33M |
| Total current assets | 91.86M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 142.71M |
| Accounts payable | 2.15M |
| Short/Current long term debt | 49.90M |
| Total current liabilities | 155.98M |
| Total liabilities | 233.25M |
| Shareholder's equity | -90.54M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -94.65M |
| Capital expenditures (TTM) | 200.00K |
| Free cash flow (TTM) | -94.85M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -674.80% |
| Return on Invested Capital | 1269.06% |
| Cash Return on Invested Capital | 125.00% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.84 |
| Daily high | 6.18 |
| Daily low | 5.62 |
| Daily Volume | 24K |
| All-time high | 1600.50 |
| 1y analyst estimate | 14.75 |
| Beta | 0.49 |
| EPS (TTM) | -128.98 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 10 Jun 2025 |
Downside potential
Loading...
Downside potential data
| ATRA | S&P500 | |
| Current price drop from All-time high | -99.61% | -14.12% |
| Highest price drop | -99.67% | -56.47% |
| Date of highest drop | 10 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -71.28% | -11.07% |
| Avg time to new high | 102 days | 12 days |
| Max time to new high | 2513 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
35.54M
Marketcap category
Small-cap
Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Employees
165
Website
Investor relations
-
SEC filings
CEO
Pascal Touchon
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page